Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN.
- Citation:
- Am J Hematol
- Year:
- 2024
- Type:
- Manuscript
- Funding:
- AFT
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Pharmas:
- Janssen Oncology
- Grants:
- Corr. Author:
- Authors:
- Rebecca Silbermann Jacob Laubach Jonathan L Kaufman Douglas W Sborov Brandi Reeves Cesar Rodriguez Ajai Chari Luciano J Costa Larry D Anderson Nitya Nathwani Nina Shah Naresh Bumma Sarah A Holstein Caitlin Costello Andrzej Jakubowiak Robert Z Orlowski Kenneth H Shain Andrew J Cowan Katharine S Gries Huiling Pei Annelore Cortoos Sharmila Patel Thomas S Lin Peter M Voorhees Saad Z Usmani Paul G Richardson
- Networks:
- CA043, CA136, CA249, FL065, LAPS-AL002, LAPS-IL057, LAPS-MA036, LAPS-NC007, LAPS-NY016, LAPS-OH007, LAPS-TX011, LAPS-TX035, LAPS-UT003, NC002, NE003, NEWMEXICO, OR013
- Study
- AFT-29 (GRIFFIN)
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: